Efficient and non-genetically modified ipsc-induced, industrialized single clone selection platform, and use
AssigneeAllife Medicine (Zhuhai) Limited
InventorsLida WU, Yuchun GU
Life of this patent
Estimating the term…
Abstract
Disclosed is an efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and a use. The platform can efficiently perform reprogramming, and only requires the use of a minimal number of reprogramming factors (OCT4, SOX2, E6, E7). During the single clone separation stage of the present invention, SSEA4/TRA-1-60 is used as a screening marker, and a large number of single cell clones are obtained by means of flow cytometry. The platform described in the present invention has advantages such as high reprogramming efficiency, high safety, easy operation, and large-scale production.
Claims11
A reprogramming factor combination for reprogramming somatic cells into inducing pluripotent stem cells, characterized in that the reprogramming factor combination is selected from OCT4, SOX2, E6, E7, KLF4, L-MYC, LIN28, NANOG, SV40LT;
- preferably, the reprogramming factor combination is OCT4, SOX2, E6, E7;
- more preferably, a form of the reprogramming factor combination includes DNA, RNA, and protein;
- most preferably, the DNA is cDNA and the RNA is mRNA.
An application, characterized in that the application comprises any of the following:
- (1) as a somatic derived induced pluripotent stem cell or cell population;
- (2) as a reprogrammed somatic cell;
- (3) as a culture medium for reprogramming somatic cells into inducing pluripotent stem cells;
- (4) as a kit for generating induced pluripotent stem cells;
- (5) as a pharmaceutical composition.
(canceled)
Dependencies are inferred from the claim text.